» Articles » PMID: 24435554

Gα12 Structural Determinants of Hsp90 Interaction Are Necessary for Serum Response Element-mediated Transcriptional Activation

Abstract

The G12/13 class of heterotrimeric G proteins, comprising the α-subunits Gα12 and Gα13, regulates multiple aspects of cellular behavior, including proliferation and cytoskeletal rearrangements. Although guanine nucleotide exchange factors for the monomeric G protein Rho (RhoGEFs) are well characterized as effectors of this G protein class, a variety of other downstream targets has been reported. To identify Gα12 determinants that mediate specific protein interactions, we used a structural and evolutionary comparison between the G12/13, Gs, Gi, and Gq classes to identify "class-distinctive" residues in Gα12 and Gα13. Mutation of these residues in Gα12 to their deduced ancestral forms revealed a subset necessary for activation of serum response element (SRE)-mediated transcription, a G12/13-stimulated pathway implicated in cell proliferative signaling. Unexpectedly, this subset of Gα12 mutants showed impaired binding to heat-shock protein 90 (Hsp90) while retaining binding to RhoGEFs. Corresponding mutants of Gα13 exhibited robust SRE activation, suggesting a Gα12-specific mechanism, and inhibition of Hsp90 by geldanamycin or small interfering RNA-mediated lowering of Hsp90 levels resulted in greater downregulation of Gα12 than Gα13 signaling in SRE activation experiments. Furthermore, the Drosophila G12/13 homolog Concertina was unable to signal to SRE in mammalian cells, and Gα12:Concertina chimeras revealed Gα12-specific determinants of SRE activation within the switch regions and a C-terminal region. These findings identify Gα12 determinants of SRE activation, implicate Gα12:Hsp90 interaction in this signaling mechanism, and illuminate structural features that arose during evolution of Gα12 and Gα13 to allow bifurcated mechanisms of signaling to a common cell proliferative pathway.

Citing Articles

Can Serotonin 7 Receptors Be a Treatment Target for Noncentral Diseases?.

Bilgin A Eurasian J Med. 2024; 55(1):S49-S54.

PMID: 39128036 PMC: 11075038. DOI: 10.5152/eurasianjmed.2023.23303.


Gα and Gα: Versatility in Physiology and Pathology.

Guo P, Tai Y, Wang M, Sun H, Zhang L, Wei W Front Cell Dev Biol. 2022; 10:809425.

PMID: 35237598 PMC: 8883321. DOI: 10.3389/fcell.2022.809425.


A Gα12-specific Binding Domain in AKAP-Lbc and p114RhoGEF.

Martin J, Cavagnini K, Brawley D, Berkley C, Smolski W, Garcia R J Mol Signal. 2019; 11:3.

PMID: 31051012 PMC: 5345129. DOI: 10.5334/1750-2187-11-3.


GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers.

Rasheed S, Leong H, Lakshmanan M, Raju A, Dadlani D, Chong F Oncogene. 2017; 37(10):1340-1353.

PMID: 29255247 PMC: 6168473. DOI: 10.1038/s41388-017-0038-6.


Cellular mechanisms of the 5-HT7 receptor-mediated signaling.

Guseva D, Wirth A, Ponimaskin E Front Behav Neurosci. 2014; 8:306.

PMID: 25324743 PMC: 4181333. DOI: 10.3389/fnbeh.2014.00306.


References
1.
Parks S, Wieschaus E . The Drosophila gastrulation gene concertina encodes a G alpha-like protein. Cell. 1991; 64(2):447-58. DOI: 10.1016/0092-8674(91)90652-f. View

2.
Adarichev V, Vaiskunaite R, Niu J, Balyasnikova I, Voyno-Yasenetskaya T . G alpha 13-mediated transformation and apoptosis are permissively dependent on basal ERK activity. Am J Physiol Cell Physiol. 2003; 285(4):C922-34. DOI: 10.1152/ajpcell.00115.2003. View

3.
Temple B, Jones C, Jones A . Evolution of a signaling nexus constrained by protein interfaces and conformational States. PLoS Comput Biol. 2010; 6(10):e1000962. PMC: 2954821. DOI: 10.1371/journal.pcbi.1000962. View

4.
Gu J, Muller S, Mancino V, Offermanns S, Simon M . Interaction of G alpha(12) with G alpha(13) and G alpha(q) signaling pathways. Proc Natl Acad Sci U S A. 2002; 99(14):9352-7. PMC: 123144. DOI: 10.1073/pnas.102291599. View

5.
Grabocka E, Wedegaertner P . Functional consequences of G alpha 13 mutations that disrupt interaction with p115RhoGEF. Oncogene. 2005; 24(13):2155-65. PMC: 1351220. DOI: 10.1038/sj.onc.1208414. View